A 52-year-old woman was diagnosed with cap polyposis (CP) with characteristic clinical, endoscopic, and histological features. By avoiding straining at defecation, her symptoms improved temporarily, however recrudesced. She was diagnosed with Helicobacter pylori (H. pylori) infection, and received eradication therapy successfully. After this eradication therapy, her symptoms and colonoscopic findings recovered completely. Only two reports in the English language literature have discussed the relationship between CP and eradication therapy for H. pylori, all patients achieved complete recovery. We recommend H. pylori testing for all cases of CP and H. pylori eradication therapy if necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.48.2547 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of in Ningxia, China.
Front Med (Lausanne)
January 2025
Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
Introduction: () is becoming more resistant to antibiotics, and the implementation of individualized therapy is highly valuable for its eradication. This study aimed to investigate the efficacy and safety of individualized treatment guided by antibiotic susceptibility testing (AST) with a 10-day or 14-day course for the eradication of .
Methods: This was a prospective, open-label, single-center, quasi-randomized trial in which 220 participants were randomized into groups based on AST results as AST-10-day ( = 98) and AST-14-day ( = 112) treatment groups.
Phage therapy in the management of respiratory and pulmonary infections: a systematic review.
Ther Adv Infect Dis
January 2025
Department of Medical Microbiology, University of Ghana Medical School, P.O. Box KB 4236, Accra, Ghana.
Background: Lower respiratory tract infections (LRTIs) pose a significant threat to global health, causing more than 2 million deaths worldwide. This menace is intensified by the alarming increase in drug resistance, which limits the availability of effective antibiotics for bacterial respiratory infections. Consequently, there is an urgent demand for alternative therapeutic options.
View Article and Find Full Text PDFRecent development of micro-nano carriers for oral antineoplastic drug delivery.
Mater Today Bio
February 2025
Department of Neurological Rehabilitation, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Chemotherapy is widely recognized as a highly efficacious modality for cancer treatment, involving the administration of chemotherapeutic agents to target and eradicate tumor cells. Currently, oral administration stands as the prevailing and widely utilized method of delivering chemotherapy drugs. However, the majority of anti-tumor medications exhibit limited solubility and permeability, and poor stability in harsh gastrointestinal environments, thereby impeding their therapeutic efficacy for chemotherapy.
View Article and Find Full Text PDFAspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants of isolates within cystic fibrosis airway mucus.
Biofilm
June 2025
CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
Antibiotics are central to managing airway infections in cystic fibrosis (CF), yet current treatments often fail due to the presence of biofilms, settling down the need for seeking therapies targeting biofilms. This study aimed to investigate the antibiofilm activity of aspartic acid and its potential as an adjuvant to tobramycin against biofilms formed by mucoid and small colony variant (SCV) tobramycin tolerant strain. We assessed the effect of aspartic acid on both surface-attached and suspended biofilms within CF artificial mucus and investigated the synergistic impact of combining it with non-lethal tobramycin concentrations.
View Article and Find Full Text PDFComparison of taurolidine with 4% ethylenediaminetetraacetic acid on antimicrobial lock effectiveness: An experimental study.
JPEN J Parenter Enteral Nutr
January 2025
3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Medical Faculty in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.
Background: Antimicrobial lock therapy is recommended for preventing and treating catheter-related bloodstream infections, but different solutions have uncertain efficacy.
Methods: Two locks, 1.35% taurolidine and 4% ethylenediaminetetraacetic acid (EDTA), were tested on Staphylococcus epidermidis, Staphylococcus aureus, methicillin-resistant S.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!